|
HAYWARD, CA, September 15, 1998 – Sepragen Corporation
(OTC BB: SPGNU, SPGNA, SPGNW) announced today its latest effort in
providing better support and services to its customers by
establishing Internet presence.
Sepragen develops and sells processes and products
using its proprietary technology for the dairy, citrus juice and
biopharmaceutical markets. Although no commercial agreements have
been reached yet, it has previously announced evaluation of these
processes by several international companies that are leaders in
their respective fields. Sepragen also continues to sell equipment
and instrumentation to biotechnology companies for use in scale-up
and manufacturing of pharmaceuticals. The company currently holds
twelve US patents and seven foreign patents relating to its
technologies. As of September 30,1997, Sepragen has 2,155,254 Class
A common shares, 701,177 Class B super voting common shares, each
convertible into one share of Class A common and 1,203,719 Class E
common shares convertible into Class B shares, but which vest only
if the Company meets certain substantial earnings thresholds or
stock price targets before December 31, 1999.
<Back
The statements in this release that
relate to future events or performance, statements about growth,
future regulatory clearances, levels of sales and market size and
future manufacturing capacity and efficiencies are forward-looking
statements that involve risks and uncertainties, including risks
associated with uncertainties related to the development of markets
for and commercial acceptance of the company's products and
services, the availability of components, competitors' product
introductions and other risks identified in the company's SEC
filings. Actual results may differ from those described in these
forward-looking statements. Readers are cautioned not to place undue
reliance on these forward-looking statements, which speak only as of
the date hereof.
|
